{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:40:55Z","timestamp":1791945655928,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA-MH002857"],"award-info":[{"award-number":["ZIA-MH002857"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NCT00088699"],"award-info":[{"award-number":["NCT00088699"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jad.2019.11.028","type":"journal-article","created":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T09:38:26Z","timestamp":1573378706000},"page":"568-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression"],"prefix":"10.1016","volume":"263","author":[{"given":"Elia E.","family":"Acevedo-Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace W.","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dede","family":"Greenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashkim","family":"Kadriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence T.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2019.11.028_bib0001","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib0002","series-title":"Diagnostic and Statistical Manual For Mental Disorders","first-page":"291","year":"2013"},{"key":"10.1016\/j.jad.2019.11.028_bib0003","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann. Stat."},{"key":"10.1016\/j.jad.2019.11.028_bib0004","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/02791072.2015.1072653","article-title":"Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine's antidepressant response and the development of ketamine addiction","volume":"47","author":"Bonnet","year":"2015","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.jad.2019.11.028_bib0005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/ALN.0b013e318242b2cd","article-title":"Ketamine-induced neuroapoptosis in the fetal and neonatal rhesus macaque brain","volume":"116","author":"Brambrink","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jad.2019.11.028_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J Trauma Stress"},{"key":"10.1016\/j.jad.2019.11.028_bib0006","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1360-0443.2001.96574910.x","article-title":"In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users","volume":"96","author":"Curran","year":"2001","journal-title":"Addiction"},{"key":"10.1016\/j.jad.2019.11.028_bib29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib30","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2019.11.028_bib0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002804","article-title":"Translating glutamate: from pathophysiology to treatment","volume":"3","author":"Javitt","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jad.2019.11.028_bib31","series-title":"Design and analysis of cross-over trials (CRC Monographs on Statistics and Applied Probability)","author":"Jones","year":"2014"},{"key":"10.1016\/j.jad.2019.11.028_bib0008","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","article-title":"Ketamine abuse potential and use disorder","volume":"126","author":"Liu","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jad.2019.11.028_bib0009","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1111\/bph.13222","article-title":"Ketamine and phencyclidine: the good, the bad and the unexpected","volume":"172","author":"Lodge","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jad.2019.11.028_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.drugalcdep.2008.01.024","article-title":"Journey through the K-hole: phenomenological aspects of ketamine use","volume":"95","author":"Muetzelfeldt","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jad.2019.11.028_bib0011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2017.11.088","article-title":"Dissociation after ketamine dosing: is the CADSS fit for purpose?","volume":"244","author":"Neehoff","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.11.028_bib32","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","article-title":"Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects","volume":"24","author":"Nugent","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib0012","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1126\/science.2660263","article-title":"Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs","volume":"244","author":"Olney","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jad.2019.11.028_bib0013","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib0014","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/da.22536","article-title":"A review of ketamine abuse and diversion","volume":"33","author":"Sassano-Higgins","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2019.11.028_bib0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/toxsci\/kfh224","article-title":"Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons","volume":"81","author":"Scallet","year":"2004","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jad.2019.11.028_bib0016","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/appi.ajp.2015.15081082","article-title":"Potential risks of poorly monitored ketamine use in depression treatment","volume":"173","author":"Schak","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib0017","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.urology.2007.01.038","article-title":"Ketamine-associated ulcerative cystitis: a new clinical entity","volume":"69","author":"Shahani","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.jad.2019.11.028_bib0018","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib0019","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ajem.2007.12.005","article-title":"Adverse events associated with ketamine for procedural sedation in adults","volume":"26","author":"Strayer","year":"2008","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.jad.2019.11.028_bib0020","unstructured":"U.S. Food & Drug Administration, 2019a. FDA approves new nasal spray medication for treatment-resistant depression."},{"key":"10.1016\/j.jad.2019.11.028_bib0021","unstructured":"U.S. Food & Drug Administration, 2019b. FDA Briefing Document: Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee Meeting. February 12, 2019FDA, Washington, DC."},{"key":"10.1016\/j.jad.2019.11.028_bib0022","series-title":"Ketalar (ketamine hydrochloride) Injection","year":"2019"},{"key":"10.1016\/j.jad.2019.11.028_bib0023","unstructured":"U.S. Food & Drug Administration, 2019d Risk evaluation and mitigation strategy (REMS) document: spravato (esketamine hydrochloride) rems program. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/rems\/Spravato_2019_03_05_REMS_Document.pdf."},{"key":"10.1016\/j.jad.2019.11.028_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jad.2017.09.023","article-title":"Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the clinician administered dissociative state scale","volume":"227","author":"van Schalkwyk","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.11.028_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.13m08852","article-title":"Ketamine safety and tolerability in clinical trials for treatment-resistant depression","volume":"76","author":"Wan","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib0026","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","article-title":"A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders","volume":"174","author":"Wilkinson","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jad.2019.11.028_bib0027","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijdevneu.2009.06.010","article-title":"Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain","volume":"27","author":"Zou","year":"2009","journal-title":"Int. J. Dev. Neurosci."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032719319834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032719319834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:05:19Z","timestamp":1778670319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032719319834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":34,"alternative-id":["S0165032719319834"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2019.11.028","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2019.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}